NCT00821535

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

An Open Label Single Dose Study To Investigate Safety And Pharmacokinetics Of Maraviroc Following A Single Oral Dose Of 300 Mg Maraviroc (Two 150 Mg Maraviroc Commercial Tablets) Under Fasting Conditions In Healthy Male Japanese Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: Male
• Age: 21 Years – 50 Years
• Healthy volunteers: Accepted

Summary

To confirm safety and pharmacokinetics of maraviroc following a single oral dose of 300 mg maraviroc in healthy male Japanese volunteers.

Conditions

• Human Immunodeficiency Virus (HIV) Infection

Interventions

Type	Name	Description
DRUG	maraviroc (Selzentry, Celsentri)	12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.

Timeline

• Start date: 2009-02-01
• Primary completion: 2009-05-01
• Completion: 2009-05-01
• First posted: 2009-01-13
• Last updated: 2010-11-16

Locations

1 site across 1 country: Singapore